EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hybrid Outer Membrane Vesicles with Genetically Engineering for Treatment of Implant‐Associated Infections and Relapse Prevention Through Host Immunomodulation

Zhichao Wang, Mingfei Li, Wenshuai Li, Liuliang He, Long Wang, Kehan Cai, Xiao Zhao, Yazhou Chen, Daifeng Li iD

Advanced Science · 2025-04 · 12 (14)

DOI: 10.1002/advs.202415379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 14.02.2025. Verfasst von Zhichao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Hauptthemen laut MEDLINE: Genetic Engineering, Immunomodulation, Prosthesis-Related Infections, Bacterial Outer Membrane. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Medical Scientist of Henan Academy of Innovations in Medical Science, Young Elite Scientists Sponsorship Program by CAST.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Implant‐associated infections (IAIs) are refractory to elimination, and the local immunosuppressive microenvironment (IME) exacerbates therapeutic difficulties, ultimately causing persistence and relapse. Therefore, exploring immunostrengthening treatments holds great promise for reversing IME and thoroughly eradicating chronic or repetitive infections. Bacterial outer membrane vesicles (OMVs) have emerged as potential immunostimulatory candidates; however, they lack active targeting capabilities and cause non‐specific inflammatory side effects. In this study, bone marrow‐derived mesenchymal stem cells (BMSCs) are genetically engineered to overexpress CXCR4 and isolated cell membranes (mBMSC CXCR4 ) for hybridization with OMVs derived from Escherichia coli ( E. coli ) to produce nanovesicles (mBMSC CXCR4 @OMV). The resulting mBMSC CXCR4 @OMV nanovesicles demonstrate excellent bone marrow targeting capability and are effectively taken up by bone marrow‐derived macrophages, triggering the efficient transition to pro‐inflammatory M1 status through TLR/NF‐κB pathway. This alteration promotes innate bactericidal capacity and antigen presentation. Subsequent activation of T and B cells and inhibition of myeloid‐derived suppressor cells (MDSCs) facilitated in vivo adaptive immunity in mouse models. Additionally, mBMSC CXCR4 @OMV boosted memory B cell and bacteria‐specific antibody responses. Together, these data highlight the potential of mBMSC CXCR4 @OMV to eradicate complicated IAIs and provide whole‐stage protection against postsurgical relapse, thus marking a significant immunotherapeutic advancement in the post‐antibiotic era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic EngineeringImmunomodulationProsthesis-Related InfectionsBacterial Outer MembraneAnimalsMiceMesenchymal Stem CellsEscherichia coliSecondary PreventionExtracellular VesiclesMice, Inbred C57BL

Stichwörter der Autor:innen

bacterial outer membrane vesiclesbone marrow targetingimmunomodulationimplant‐associated infectionsrelapse prevention

Autor:innen und Institutionen

  • Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
  • Medical 3D Printing Center, The First Affiliated Hospital of Zhengzhou University, Henan Institute of Advanced Technology of Zhengzhou University, Zhengzhou, 450052, China.
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China.

ORCID-Profile: Daifeng Li

Förderung

  • National Natural Science Foundation of China
  • Clinical Medical Scientist of Henan Academy of Innovations in Medical Science
  • Young Elite Scientists Sponsorship Program by CAST
  • Young and Middle-Aged Discipline Leader of Henan Provincial Health Commission
  • Natural Science Foundation of Henan Province

Zitieren

APA

Wang, Z., Li, M., Li, W., He, L., Wang, L., Cai, K., Zhao, X., Chen, Y., & Li, D. (2025). Hybrid Outer Membrane Vesicles with Genetically Engineering for Treatment of Implant‐Associated Infections and Relapse Prevention Through Host Immunomodulation. Advanced Science, 12(14). https://doi.org/10.1002/advs.202415379

Vancouver

Wang Z, Li M, Li W, He L, Wang L, Cai K, et al. Hybrid Outer Membrane Vesicles with Genetically Engineering for Treatment of Implant‐Associated Infections and Relapse Prevention Through Host Immunomodulation. Advanced Science. 2025;12(14). doi:10.1002/advs.202415379

BibTeX
@article{Wang2025,
  author = {Wang, Zhichao and Li, Mingfei and Li, Wenshuai and He, Liuliang and Wang, Long and Cai, Kehan and Zhao, Xiao and Chen, Yazhou and Li, Daifeng},
  title = {Hybrid Outer Membrane Vesicles with Genetically Engineering for Treatment of Implant‐Associated Infections and Relapse Prevention Through Host Immunomodulation},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {14},
  doi = {10.1002/advs.202415379}
}
Kostenlos starten →